• Homect_img
  • About Usct_img
  • NewsRoomct_img
  • SARAH CANNON RESEARCH INSTITUTE (SCRI) ABSTRACT ACCEPTED FOR PRESENTATION AT ASCO BREAST CANCER SYMPOSIUM
Required Fields *
Submit Close
Print

Let Our Family Care for Your Family!

SARAH CANNON RESEARCH INSTITUTE (SCRI) ABSTRACT ACCEPTED FOR PRESENTATION AT ASCO BREAST CANCER SYMPOSIUM

September 07, 2011


 

NASHVILLE, TN., Sept. 7, 2011 – SCRI Breast Cancer Senior Investigator Denise A. Yardley, M.D. will present findings of ENCORE 301, an advanced breast cancer study, at the 2011 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium September 8-10 in San Francisco, CA.

 

ENCORE 301 (ENtinostat Combinations Overcoming REsistance) is a multicenter, randomized  phase II study of exemestane with and without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer, progressing on treatment with the non-steroidal aromatase inhibitors anastrozole or letrozole. The endpoints of the study include progression free survival (PFS), overall survival (OS) and safety.

 

“Unfortunately, resistance to hormonal therapies develops over time in women with advanced breast cancer, leading to discontinuation of that treatment, and the resulting need for chemotherapy,” said Dr. Yardley. “The study was designed to evaluate whether the addition of entinostat (a class I specific histone deacetylase inhibitor) combined with exemestane can extend the benefit of hormone therapy by delaying the development of resistance and subsequent disease progression.” 

 

Dr. Yardley will present the data in an oral and poster session at the conference. Details are as follows:

 

Session

Reception and General Poster Session D 

General Session VIII: Advances in Hormone Receptor-positive Breast Cancer and Host Factors

Session Type

General Poster Session 

General Session (oral)

Date and Time

9/9/11, 4:30-5:45 p.m. PT 

9/10/11, 10:00-11:30 a.m. PT

Abstract#:

268 

268

 

About Breast Cancer and Hormone Therapy  

Annually about 207,000 women have breast cancer in the United States and about 20,000 of them have metastatic breast cancer (MBC). Approximately 70 percent of women with breast cancer have ER+ breast cancer.

 

About SCRI

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology, cardiology, gastroenterology and other therapeutic areas through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites. For more information, please visit us at sarahcannonresearch.com, or on Facebook or Twitter.

Our News

View All News